Targeting the MET Receptor Tyrosine Kinase as a Strategy for Radiosensitization in Locoregionally Advanced Head and Neck Squamous Cell Carcinoma.

Animals Disease Models, Animal Humans Mice Protein Kinase Inhibitors / therapeutic use Radiation-Sensitizing Agents / therapeutic use Squamous Cell Carcinoma of Head and Neck / drug therapy Xenograft Model Antitumor Assays

Journal

Molecular cancer therapeutics
ISSN: 1538-8514
Titre abrégé: Mol Cancer Ther
Pays: United States
ID NLM: 101132535

Informations de publication

Date de publication:
02 2020
Historique:
received: 13 11 2018
revised: 19 08 2019
accepted: 14 11 2019
pubmed: 21 11 2019
medline: 12 1 2021
entrez: 21 11 2019
Statut: ppublish

Résumé

Radiotherapy (RT) along with surgery is the mainstay of treatment in head and neck squamous cell carcinoma (HNSCC). Radioresistance represents a major source of treatment failure, underlining the urgent necessity to explore and implement effective radiosensitization strategies. The MET receptor widely participates in the acquisition and maintenance of an aggressive phenotype in HNSCC and modulates the DNA damage response following ionizing radiation (IR). Here, we assessed MET expression and mutation status in primary and metastatic lesions within a cohort of patients with advanced HNSCC. Moreover, we investigated the radiosensitization potential of the MET inhibitor tepotinib in a panel of cell lines,

Identifiants

DOI: 10.1158/1535-7163.MCT-18-1274 PMID: 31744898
pubmed: 31744898
pii: 1535-7163.MCT-18-1274
doi: 10.1158/1535-7163.MCT-18-1274
doi:

Substances chimiques

Protein Kinase Inhibitors 0
Radiation-Sensitizing Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

614-626

Informations de copyright

©2019 American Association for Cancer Research.

Auteurs

Lluís Nisa (L)

Department for BioMedical Research, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland.
Department of Radiation Oncology, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland.
Department of Otorhinolaryngology - Head and Neck Surgery, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland.

Paola Francica (P)

Department for BioMedical Research, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland.
Department of Radiation Oncology, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland.

Roland Giger (R)

Department of Otorhinolaryngology - Head and Neck Surgery, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland.

Matúš Medo (M)

Department for BioMedical Research, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland.
Department of Radiation Oncology, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland.

Olgun Elicin (O)

Department of Radiation Oncology, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland.
ORCID: 0000-0002-6996-0646

Manja Friese-Hamim (M)

Translational Innovation Platform Oncology, Merck HealthCare KGaA, Darmstadt, Germany.

Claudia Wilm (C)

Translational Innovation Platform Oncology, Merck HealthCare KGaA, Darmstadt, Germany.

Christopher Stroh (C)

Translational Innovation Platform Oncology, Merck HealthCare KGaA, Darmstadt, Germany.

Beat Bojaxhiu (B)

Department of Radiation Oncology, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland.

Aurélie Quintin (A)

Department for BioMedical Research, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland.
Department of Radiation Oncology, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland.

Marco D Caversaccio (MD)

Department of Otorhinolaryngology - Head and Neck Surgery, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland.

Matthias S Dettmer (MS)

Institute of Pathology, University of Bern, Bern, Switzerland.
ORCID: 0000-0003-0948-1392

Mélanie Buchwalder (M)

Department of Otorhinolaryngology - Head and Neck Surgery, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland.
Institute of Pathology, University of Bern, Bern, Switzerland.

Tess M Brodie (TM)

Department for BioMedical Research, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland.
Department of Radiation Oncology, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland.
Mass Cytometry Facility, University of Zurich, Zurich, Switzerland.

Daniel M Aebersold (DM)

Department for BioMedical Research, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland.
Department of Radiation Oncology, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland.
ORCID: 0000-0002-9493-3834

Yitzhak Zimmer (Y)

Department for BioMedical Research, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland.
Department of Radiation Oncology, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland.

Thomas E Carey (TE)

Department of Otolaryngology - Head and Neck Surgery, University of Michigan School of Medicine, Ann Arbor, Michigan.
Comprehensive Cancer Center, University of Michigan School of Medicine, Ann Arbor, Michigan.
ORCID: 0000-0002-5202-7518

Michaela Medová (M)

Department for BioMedical Research, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland. michaela.medova@dbmr.unibe.ch.
Department of Radiation Oncology, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland.
ORCID: 0000-0003-0649-469X

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Targeting the MET Receptor Tyrosine Kinase as...
questionsmedicales.fr › Techniques d'investigation › Modèles théoriques › Modèles biologiques › Modèles animaux de maladie humaine › Targeting the MET Receptor Tyrosine Kinase as...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Targeting the MET Receptor Tyrosine Kinase as...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Targeting the MET Receptor Tyrosine Kinase as...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Mécanismes moléculaires de l'action pharmacologique › Antienzymes › Inhibiteurs de protéines kinases › Targeting the MET Receptor Tyrosine Kinase as...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Radiosensibilisants › Targeting the MET Receptor Tyrosine Kinase as...
questionsmedicales.fr › Tumeurs › Tumeurs par siège › Tumeurs de la tête et du cou › Carcinome épidermoïde de la tête et du cou › Targeting the MET Receptor Tyrosine Kinase as...
questionsmedicales.fr › Techniques d'investigation › Transplantation tumorale › Tests d'activité antitumorale sur modèle de xénogreffe › Targeting the MET Receptor Tyrosine Kinase as...